daratumumab

Kerri FitzgeraldMyeloma | November 16, 2022
This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma...
Leah LawrenceMyeloma | November 22, 2022
The use of the CD38-directed monoclonal antibody daratumumab was associated with ocular events...
Leah SherwoodMyeloma | November 16, 2022
The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%...
Advertisement
Leah SherwoodMyeloma | November 16, 2022
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
Jacob Laubach, MD, MPPMyeloma | November 14, 2022
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Jacob Laubach, MD, MPPMyeloma | November 14, 2022
Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.
Advertisement
Advertisement
Advertisement